logo
French pharma giant swoops on British vaccine champion in $1.6bn deal

French pharma giant swoops on British vaccine champion in $1.6bn deal

Daily Mail​5 days ago
French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up to $1.6billion (£1.2billion).
The deal sees Sanofi take control of Vicebio's early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
London-based Vicebio says it is 'redefining how the world combats respiratory diseases', with its 'Molecular Clamp' tech enabling the development of next-generation vaccines that offer 'broad protection, ready-to-use formulations, and high manufacturability'.
Vicebio's vaccine candidate complements Sanofi's existing range, and allows it to offer a wider range to doctors and patients.
The French group said on Tuesday it would pay an initial $1.15billion for the London-based respiratory diseases specialist, with a further $450million in milestone payments to be paid based on development and regulatory progress.
Sanofi will also gain Vicebio's molecular clamp tech, which is used to help an immune system to recognise and respond to viral proteins more quickly.
The acquisition is expected to close in the fourth quarter of 2025. Sanofi says it won't have a significant impact on its 2025 financial guidance.
Jean-François Toussaint, global head of research and development vaccines at Sanofi, said: 'Vicebio's Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine designs at a time when respiratory viral infections continue to impact millions globally.
'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation.'
The acquisition follows a number of recent purchases by Sanofi, following Vigil Neuroscience in May and the DR-0201 cell engager from Dren Bio in March.
rMost recently, Sanofi completed its acquisition of Blueprint Medicines last month.
Emmanuel Heron, chief executive of Vicebio, said: 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realize the potential of our innovative technology.
'We look forward to advancing our platform and pipeline to deliver meaningful benefits for patients and public health.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ALEX BRUMMER: Bank fears Farage turmoil in No 10
ALEX BRUMMER: Bank fears Farage turmoil in No 10

Daily Mail​

time16 minutes ago

  • Daily Mail​

ALEX BRUMMER: Bank fears Farage turmoil in No 10

As a public figure, the governor of the Bank of England Andrew Bailey receives most attention from consumers and businesses alike for his role in setting interest rates. Critical as that is to national wellbeing, it has long been my belief that Bailey is more comfortable with the Bank's other, less discussed role of maintaining financial stability. Bailey was first to the battlements in his early days in office in March 2020 as the pandemic shut down Britain and much of the world. Bond markets in New York were in panic, and the Bank, led first by Mark Carney and then Bailey, moved to calm events. A currency swap deal with the US was activated, interest rates were cut to the bone and more money printing, through quantitative easing, was authorised. Bailey passionately urged government to take steps to prevent scarring to the economy. He was also at the tiller in the autumn of 2022 when Liz Truss's tax-cutting mini Budget sparked a run on the pound and a sudden retreat from British government bonds. The scale and suddenness of the move caused ructions for pension funds which had used derivative products to gamble on returns. The episode had threatened, without Bailey's intervention, to cause a cascade of financial collapses among banks who had provided credit for the trades. The Bank of England became a butt of criticism, not least on these pages. Its twice-yearly Financial Stability Report had in the past warned of the potential danger of liability driven-investment products (LDIs) but neither the Bank nor the Pensions Regulator addressed the matter. It is one thing for the Financial Stability Committee to identify and warn of dangers to the financial system, but quite another to tackle a weakness and close it down. Bailey was in the Bank's engine room in the Great Financial Crisis of 2008, so has vast experience of dealing with fractures in the financial system and knows how rapidly contagion takes place. All this experience tells him that Chancellor Rachel Reeves' efforts to encourage growth, by deregulating the City, could be a huge error. It is a reminder of the light touch regulation in the run-up to the collapse of Northern Rock in 2007 and the crisis which followed. Readers of this month's Financial Stability document would find few clues to what Bailey believes is the most acute concern at present. It is not Trump tariffs or the present Government's borrowing needs, as serious as they may be. The governor's biggest worry is political uncertainty. It may seem mad to think that this should be the case given Labour's vast Commons majority and four more years in office. The significant statistic is that Nigel Farage's Reform UK has led the other parties in 65 consecutive polls. And the present kerfuffles in Epping and the record small boat arrivals in a long hot summer make the potential for a Farage journey to Downing Street ever more credible. Bailey and the independent Bank never indulge in party politics. But for the governor, pound sterling, the bond markets and the whole stability of the financial system, the number one threat is a big-spending populist released into Downing Street. Reach for the safety straps.

Charging point shortage dents demand for EVs
Charging point shortage dents demand for EVs

Daily Mail​

time19 minutes ago

  • Daily Mail​

Charging point shortage dents demand for EVs

A shortage of charging points is denting demand for electric vehicles, according to industry experts. Figures show there are just 82,369 public chargers in the UK with 48 added each day on average so far this year. Analysis by the Mail reveals Britain needs to build around 130 a day – nearly triple the current number – to reach the goal of having 300,000 public charging points by 2030. The shortage of charging points – which has fuelled so-called 'range anxiety' among motorists worried about where they can plug in – has been highlighted as one of the reasons why demand for electric cars has dwindled. Drivers have also been put off by the price of electric vehicles, which are typically more expensive than petrol and diesel cars. The Government has this summer announced plans to give motorists up to £3,750 to switch to EVs in a bid to boost demand to meet net zero targets. But experts said the shortage of charging points was a major threat to these efforts. Quentin Willson, founder of FairCharge, said the Government 'should do more to fast track and better support installations, especially in areas where there are charging deserts'. He added: 'Consumers rightly worry that there aren't enough public chargers. 'Government needs to send out a clear message to drivers that they are in control of the EV charging narrative, that they will support investment into the charging sector and help keep prices down.' According to charging point statistics website Zapmap, about 8,670 were added to the public network in the first half of this year. But this is less than half of the 19,834 added in 2024, suggesting the rollout is slowing. Just 1,371 were added to the Zapmap database in June – or 46 a day. Susan Wells, a director of EV charging point firm Hive, said: 'Charging must become as straightforward as filling up a petrol or diesel car.' A Department for Transport spokesman said: 'We're adding a public charge point every half an hour.

Unilever ice cream spinoff should free up cash
Unilever ice cream spinoff should free up cash

Daily Mail​

time19 minutes ago

  • Daily Mail​

Unilever ice cream spinoff should free up cash

Unilever is set to update investors on the listing of its ice cream business this week. The consumer goods giant spun off the division behind Magnum (advertised by actress Eva Longoria), Ben & Jerry's and Wall's at the start of this month after snubbing London for an Amsterdam listing earlier this year. The group – whose brands also include Dove, Comfort and Hellmann's – will update investors on its plans for a fourth quarter listing on Thursday. Aarin Chiekrie, from broker Hargreaves Lansdown, said the ice cream demerger should 'free up plenty of cash to pay down debts and invest in other, higher-returning areas of the business'. It is looking to save £700m by cutting 7,500 jobs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store